Morphic Holding, Inc. (MORF)

29.90 +1.19 (+4.14%) At close: 04:00PM EDT

Morphic Holding, Inc.

35 Gatehouse Drive, A2
Waltham, MA 02451
United States
781 996 0955
https://www.morphictx.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 124

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Praveen P. Tipirneni M.D.	CEO, MD & Director	1.04M	N/A	1968
Dr. Bruce N. Rogers Ph.D.	President	857.34k	N/A	1969
Dr. Timothy A. Springer Ph.D.	Founder, Independent Director & Member of Scientific Advisory Board	40k	N/A	1948
Dr. Marc Schegerin M.B.A., M.D.	CFO & COO	769.25k	N/A	1976
Mr. Robert E. Farrell Jr., CPA	Senior VP of Finance & Chief Accounting Officer	645.5k	N/A	1965
Dr. Blaise Lippa Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Mr. William D. DeVaul Esq.	General Counsel & Secretary	601.44k	4.32M	1971
Mr. Aaron Pelta	Senior Vice President of Business & Corporate Development	N/A	N/A	N/A
Ms. Joanne Gibbons	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Simon Cooper MBBS	Chief Medical Officer	N/A	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Corporate governance

Morphic Holding, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 4; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.